Exploring Clinical Characteristics and Treatment Outcomes of Squamous Cell Lung Cancers Harboring EGFR and ALK Mutations: A Case Series

被引：0
|
作者：
Chattopadhyay, P. [1 ]
Sureshkumar, K. [2 ]
Kareff, S. [1 ,3 ]
Rodriguez, E. [1 ,3 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
[2] Univ Miami, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Squamous cell cancer of lung; EGFR; ALK;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.12E.05
引用
收藏
页码：S654 / S654
页数：1
相关论文
共 50 条
  • [31] Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
    Kim, Hye Ryun
    Shim, Hyo Sup
    Chung, Jin-Haeng
    Lee, Young Joo
    Hong, Yun Kyoung
    Rha, Sun Young
    Kim, Se Hoon
    Ha, Sang-Jun
    Kim, Se Kyu
    Chung, Kyung Young
    Soo, Ross
    Kim, Joo Hang
    Cho, Byoung Chul
    CANCER, 2012, 118 (03) : 729 - 739
  • [32] CLINICAL CHARACTERISTICS OF PATIENTS WITH NON SMALL-CELL LUNG CANCER HARBORING EGFR MUTATION OR EML4-ALK IN CHINESE HAN ETHNICITY POPULATION
    Li, Aiwu
    Ren, Shengxiang
    Chen, Xiaoxia
    Ni, Jian
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S468 - S468
  • [33] Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients
    Tian, Guangming
    Zhao, Xinliang
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Chen, Xiaoling
    Han, Jindi
    Ma, Xiangjuan
    Wu, Di
    Han, Sen
    Long, Jieran
    Wang, Yang
    Fang, Jian
    FUTURE ONCOLOGY, 2016, 12 (10) : 1243 - 1249
  • [34] Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?
    Chiu, Chao-Hua
    Chou, Teh-Ying
    Chiang, Chi-Lu
    Tsai, Chun-Ming
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (04) : 661 - 665
  • [35] Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?
    Chao-Hua Chiu
    Teh-Ying Chou
    Chi-Lu Chiang
    Chun-Ming Tsai
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 661 - 665
  • [36] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [37] Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2024, 19 : 125 - 125
  • [38] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2023, 18 : 807 - 817
  • [39] Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer
    Mori, Mio
    Hayashi, Hideyuki
    Fukuda, Minoru
    Honda, Sumihisa
    Kitazaki, Takeshi
    Shigematsu, Kazuto
    Matsuyama, Naohiro
    Otsubo, Mayumi
    Nagayasu, Takeshi
    Hashisako, Mikiko
    Tabata, Kazuhiro
    Uetani, Masataka
    Ashizawa, Kazuto
    THORACIC CANCER, 2019, 10 (04) : 872 - 879
  • [40] Overall survival in patients with advanced non-small cell lung cancer harboring concomitant EGFR mutations and ALK rearrangements: A cohort study
    Zhou, Qing
    Yang, Jinji
    Zhang, Xuchao
    Chan, Huajun
    Su, Jian
    Tu, Hai-Yan
    Yan, Hong-Hong
    Wang, Zhen
    Xu, Chongrui
    Huang, Yisheng
    Jiang, Ben-Yuan
    Wang, Bin-Chao
    Bai, Xiao-Yan
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345